Fermenta Biotech Q4 FY26: Revenue ₹547.8 Cr, PAT ₹18.6 Cr
Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹122Cr
- −13.1% YoY
- −11.5% QoQ
- Net profit
- ₹19Cr
- −44.2% YoY
- +54.7% QoQ
- Margin
- 16.45%
- −10 pp YoY
- −1.7 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Fermenta Biotech Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY - Q4 FY26 EBITDA: ₹122.2 crore, up 0.5% YoY - Q4 FY26 Profit After Tax (PAT): ₹25.1 crore, down 39% YoY - FY26 Core Revenue (excluding real estate): ₹546 crore, up 27% YoY - Vitamin D3 Human Nutrition Revenue: ₹293 crore, up 28% YoY - Vitamin D3 Animal Nutrition Revenue: ₹109 crore, up 32% YoY - Green Chemistry Sales: ₹16 crore, up 126% YoY - Real estate value unlocking declined significantly (INR 45 crore in FY25 vs INR 2 crore in FY26) impacting headline figures - Q4/FY26 EBITDA: ₹25.1 crore, down 39% YoY (Page 5) - Q4/FY26 Profit after Tax (PAT): ₹18.6 crore, down 44% YoY (Page 5) - Operating margin: EBITDA margin held at 22.3% (Page 5) - Revenue for Q4/
From Fermenta Biotech Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY
- Q4 FY26 EBITDA: ₹122.2 crore, up 0.5% YoY
- Q4 FY26 Profit After Tax (PAT): ₹25.1 crore, down 39% YoY
- FY26 Core Revenue (excluding real estate): ₹546 crore, up 27% YoY
- Vitamin D3 Human Nutrition Revenue: ₹293 crore, up 28% YoY
- Vitamin D3 Animal Nutrition Revenue: ₹109 crore, up 32% YoY
- Green Chemistry Sales: ₹16 crore, up 126% YoY
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for FY26 was INR 30 crore, up from INR 22 crore in FY25, focused on capacity readiness (Page 11).
- Investing cash flow showed a net outflow of INR 43 crore in FY26, mainly on capacity additions (Page 11).
- Capacity expansion driver mentioned: employee cost increased to 16% in FY26 from 15% in FY25, indicating headcount addition due to capacity growth (Page 12).
2 more points from Fermenta Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 122 | 140 | -13.1% | 137 | -11.5% |
| Operating profit (EBITDA) | 20 | 37 | -45.9% | 25 | -19.9% |
| Operating margin | 16.45% | 26.42% | -10 pp | 18.17% | -1.7 pp |
| Profit before tax | 26 | 32 | -18.1% | 17 | +49.9% |
| Net profit (PAT) | 19 | 33 | -44.2% | 12 | +54.7% |
| EPS (₹) | 6.52 | 11.68 | -44.2% | 4.31 | +51.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q4 FY26 results?
Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY - Q4 FY26 EBITDA: ₹122.2 crore, up 0.5% YoY - Q4 FY26 Profit After Tax (PAT): ₹25.1 crore, down 39% YoY - FY26 Core Revenue (excluding real estate): ₹546 crore, up 27% YoY - Vitamin D3 Human Nutrition Revenue: ₹293 crore, up 28% YoY - Vitamin D3 Animal Nutrition Revenue: ₹109 crore, up 32% YoY - Green Chemistry Sales: ₹16 crore, up 126% YoY - Real estate value unlocking declined significantly (INR 45 crore in FY25 vs INR 2 crore in FY26) impacting headline figures - Q4/FY26 EBITDA: ₹25.1 crore, down 39% YoY (Page 5) - Q4/FY26 Profit after Tax (PAT): ₹18.6 crore, down 44% YoY (Page 5) - Operating margin: EBITDA margin held at 22.3% (Page 5) - Revenue for Q4/
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
Capex for FY26 was INR 30 crore, up from INR 22 crore in FY25, focused on capacity readiness (Page 11).
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
